跳转至内容
Merck

D3821

Sigma-Aldrich

地伐西匹

≥98% (HPLC), powder

别名:

(S)-N-(2,3-二氢-1-甲基-2-氧代-5-苯基-1H-1,4-苯并二氮杂-3-基)吲哚-2-甲酰胺, L-364,718, MK 329

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C25H20N4O2
分子量:
408.45
MDL號碼:
分類程式碼代碼:
12352200
PubChem物質ID:
NACRES:
NA.77

品質等級

化驗

≥98% (HPLC)

形狀

powder

儲存條件

desiccated

顏色

white to off-white

溶解度

DMSO: >5 mg/mL

起源

Merck & Co., Inc., Kenilworth, NJ, U.S.

儲存溫度

2-8°C

SMILES 字串

CN1C(=O)[C@@H](NC(=O)c2cc3ccccc3[nH]2)N=C(c4ccccc4)c5ccccc15

InChI

1S/C25H20N4O2/c1-29-21-14-8-6-12-18(21)22(16-9-3-2-4-10-16)27-23(25(29)31)28-24(30)20-15-17-11-5-7-13-19(17)26-20/h2-15,23,26H,1H3,(H,28,30)/t23-/m1/s1

InChI 密鑰

NFHRQQKPEBFUJK-HSZRJFAPSA-N

一般說明

地伐西匹通过化学修饰而衍生自阿斯匹林,具有苯并二氮杂骨架。

應用

地伐西匹在人胚胎肾293T细胞和人胰腺切片中已被用作胆囊收缩素受体1(CCK1R)拮抗剂。

生化/生理作用

地伐西匹是一种CCK1(CCK-A)受体拮抗剂和CCK8拮抗剂。
地伐西匹是一种胆囊收缩素受体1(CCK1R)拮抗剂。它可抑制CCK与外周型受体(CCK-A)的结合。地伐西匹可逆转胆囊收缩素八肽(CCK-8)对吗啡的拮抗作用。

特點和優勢

该化合物是由Merck & Co., Inc., Kenilworth, NJ, U.S.开发的。想要浏览其他由制药公司开发的化合物以及已批准药物/候选药物清单, 请单击此处

象形圖

Skull and crossbones

訊號詞

Danger

危險聲明

危險分類

Acute Tox. 1 Oral

儲存類別代碼

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

其他客户在看

Clémence Blouet et al.
PloS one, 7(12), e51898-e51898 (2012-12-20)
Previous evidence indicates that duodenal lipid sensing engages gut-brain neurocircuits to determine food intake and hepatic glucose production, but a potential role for gut-brain communication in the control of energy expenditure remains to be determined. Here, we tested the hypothesis
Yuki Orikawa et al.
Molecular pain, 6, 72-72 (2010-10-29)
Z-360 is an orally active cholecystokinin-2 (CCK2)/gastrin receptor antagonist currently under development as a therapeutic drug for pancreatic cancer. It was previously reported that Z-360 treatment in combination with gemcitabine prolonged the survival period in a lethal pancreatic cancer xenograft
Development of a CCK1R-membrane nanoparticle as a fish-out tool for bioactive peptides
Staljanssens D, et al.
Peptides, 68, 219-227 (2015)
Kaleeckal G Harikumar et al.
Assay and drug development technologies, 9(4), 394-402 (2011-03-15)
The success in screening for drug candidates is highly dependent on the power of the strategy implemented. In this work, we report and characterize a novel fluorescent benzodiazepine antagonist of the type 1 cholecystokinin receptor (3-(3-(7-fluoro-1-(2-isopropyl(4-methoxyphenyl)amino)-2-oxoethyl)-2,4-dioxo-5-phenyl-2,3,4,5-tetrahydro-1H-benzo[b][1,4]-diazepin-3-yl)ureido)benzoic acid) that can be
X-M Wu et al.
Journal of animal physiology and animal nutrition, 96(2), 214-219 (2011-03-29)
Total parenteral nutrition (TPN) results in atrophy of the pancreas, while cholecystokinin (CCK) can significantly stimulate the exocrine pancreas in rodents. This study was designed to examine whether CCK may improve the atrophy of the pancreas in rats on TPN

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门